These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Agonistic Anti-CD40 Antibody Triggers an Acute Liver Crisis With Systemic Inflammation in Humanized Sickle Cell Disease Mice. Yalamanoglu A; Dubach IL; Schulthess N; Ingoglia G; Swindle DC; Humar R; Schaer DJ; Buehler PW; Irwin DC; Vallelian F Front Immunol; 2021; 12():627944. PubMed ID: 33763072 [TBL] [Abstract][Full Text] [Related]
5. MASP-2 and MASP-3 inhibitors block complement activation, inflammation, and microvascular stasis in a murine model of vaso-occlusion in sickle cell disease. Belcher JD; Nguyen J; Chen C; Abdulla F; Conglin R; Ivy ZK; Cummings J; Dudler T; Vercellotti GM Transl Res; 2022 Nov; 249():1-12. PubMed ID: 35878790 [TBL] [Abstract][Full Text] [Related]
6. Xanthine Oxidase Drives Hemolysis and Vascular Malfunction in Sickle Cell Disease. Schmidt HM; Wood KC; Lewis SE; Hahn SA; Williams XM; McMahon B; Baust JJ; Yuan S; Bachman TN; Wang Y; Oh JY; Ghosh S; Ofori-Acquah SF; Lebensburger JD; Patel RP; Du J; Vitturi DA; Kelley EE; Straub AC Arterioscler Thromb Vasc Biol; 2021 Feb; 41(2):769-782. PubMed ID: 33267657 [TBL] [Abstract][Full Text] [Related]
7. Impaired Bile Secretion Promotes Hepatobiliary Injury in Sickle Cell Disease. Vats R; Liu S; Zhu J; Mukhi D; Tutuncuoglu E; Cardenes N; Singh S; Brzoska T; Kosar K; Bamne M; Jonassaint J; Adebayo Michael A; Watkins SC; Hillery C; Ma X; Nejak-Bowen K; Rojas M; Gladwin MT; Kato GJ; Ramakrishnan S; Sundd P; Monga SP; Pradhan-Sundd T Hepatology; 2020 Dec; 72(6):2165-2181. PubMed ID: 32190913 [TBL] [Abstract][Full Text] [Related]
8. Pathophysiology of Sickle Cell Disease. Sundd P; Gladwin MT; Novelli EM Annu Rev Pathol; 2019 Jan; 14():263-292. PubMed ID: 30332562 [TBL] [Abstract][Full Text] [Related]
9. Long-Term L-Glutamine Treatment Reduces Hemolysis without Ameliorating Hepatic Vaso-Occlusion and Liver Fibrosis in a Mouse Model of Sickle Cell Disease. Katoch O; Ungalara R; Kaminski T; Li Z; Dubey RK; Burholt I; Gudapati S; Pradhan-Sundd T Biomedicines; 2023 Aug; 11(9):. PubMed ID: 37760853 [TBL] [Abstract][Full Text] [Related]
10. Olinciguat, a stimulator of soluble guanylyl cyclase, attenuates inflammation, vaso-occlusion and nephropathy in mouse models of sickle cell disease. Tchernychev B; Li H; Lee SK; Gao X; Ramanarasimhaiah R; Liu G; Hall KC; Bernier SG; Jones JE; Feil S; Feil R; Buys ES; Graul RM; Frenette PS; Masferrer JL Br J Pharmacol; 2021 Sep; 178(17):3463-3475. PubMed ID: 33864386 [TBL] [Abstract][Full Text] [Related]
11. Mouse models of sickle cell disease: Imperfect and yet very informative. Kamimura S; Smith M; Vogel S; Almeida LEF; Thein SL; Quezado ZMN Blood Cells Mol Dis; 2024 Jan; 104():102776. PubMed ID: 37391346 [TBL] [Abstract][Full Text] [Related]
12. Dietary supplementation with sulforaphane attenuates liver damage and heme overload in a sickle cell disease murine model. Panda H; Keleku-Lukwete N; Kuga A; Fuke N; Suganuma H; Suzuki M; Yamamoto M Exp Hematol; 2019 Sep; 77():51-60.e1. PubMed ID: 31404577 [TBL] [Abstract][Full Text] [Related]
13. The oral ferroportin inhibitor vamifeport improves hemodynamics in a mouse model of sickle cell disease. Nyffenegger N; Zennadi R; Kalleda N; Flace A; Ingoglia G; Buzzi RM; Doucerain C; Buehler PW; Schaer DJ; Dürrenberger F; Manolova V Blood; 2022 Aug; 140(7):769-781. PubMed ID: 35714304 [TBL] [Abstract][Full Text] [Related]
14. Amiodarone improves anemia in a murine model of sickle cell disease and is associated with increased erythrocyte bis(monoacylglycerol) phosphate. Venugopal J; Wang J; Guo C; Eitzman DT Sci Rep; 2022 Sep; 12(1):16437. PubMed ID: 36180774 [TBL] [Abstract][Full Text] [Related]
15. Neutrophils as drivers of vascular injury in sickle cell disease. Torres LS; Hidalgo A Immunol Rev; 2023 Mar; 314(1):302-312. PubMed ID: 36251624 [TBL] [Abstract][Full Text] [Related]
16. The fucosylation inhibitor, 2-fluorofucose, inhibits vaso-occlusion, leukocyte-endothelium interactions and NF-ĸB activation in transgenic sickle mice. Belcher JD; Chen C; Nguyen J; Abdulla F; Nguyen P; Nguyen M; Okeley NM; Benjamin DR; Senter PD; Vercellotti GM PLoS One; 2015; 10(2):e0117772. PubMed ID: 25706118 [TBL] [Abstract][Full Text] [Related]
17. Control of Oxidative Stress and Inflammation in Sickle Cell Disease with the Nrf2 Activator Dimethyl Fumarate. Belcher JD; Chen C; Nguyen J; Zhang P; Abdulla F; Nguyen P; Killeen T; Xu P; O'Sullivan G; Nath KA; Vercellotti GM Antioxid Redox Signal; 2017 May; 26(14):748-762. PubMed ID: 26914345 [TBL] [Abstract][Full Text] [Related]
18. SC411 treatment can enhance survival in a mouse model of sickle cell disease. Wu CYC; Lopez-Toledano MA; Daak AA; Clemons GA; Citadin CT; Sancilio FD; Rabinowicz AL; Minagar A; Neumann JT; Lee RHC; Lin HW Prostaglandins Leukot Essent Fatty Acids; 2020 Jul; 158():102110. PubMed ID: 32447175 [TBL] [Abstract][Full Text] [Related]
19. Sickle cell disease in mice is associated with sensitization of sensory nerve fibers. Kenyon N; Wang L; Spornick N; Khaibullina A; Almeida LE; Cheng Y; Wang J; Guptill V; Finkel JC; Quezado ZM Exp Biol Med (Maywood); 2015 Jan; 240(1):87-98. PubMed ID: 25070860 [TBL] [Abstract][Full Text] [Related]
20. Mitapivat increases ATP and decreases oxidative stress and erythrocyte mitochondria retention in a SCD mouse model. Quezado ZMN; Kamimura S; Smith M; Wang X; Heaven MR; Jana S; Vogel S; Zerfas P; Combs CA; Almeida LEF; Li Q; Quezado M; Horkayne-Szakaly I; Kosinski PA; Yu S; Kapadnis U; Kung C; Dang L; Wakim P; Eaton WA; Alayash AI; Thein SL Blood Cells Mol Dis; 2022 Jul; 95():102660. PubMed ID: 35366607 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]